Accreditation/Credit Designation
Medical Crossfire®: Practical Considerations for Integrations of Biosimilars Into Patient Care Pathways for Hematologic Malignancies, Rome, Italy, 27/09/2021-27/09/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participationinternational-activities.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
EACCME Credits
Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.
In order to help you issue individual certificates to each participant, please find below the breakdown of ECMEC®s per day: 28.09.2021 - 1.00
The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.
ACCME Credits
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by an educational grant from Pfizer Inc.
Medical Crossfire®: Practical Considerations for Integrations of Biosimilars Into Patient Care Pathways for Hematologic Malignancies
Release Date: November 1, 2021
Expiration Date: November 1, 2022
Activity Overview
This educational activity is an archive of the live virtual symposium held on September 27, 2021.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Pfizer Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Outline the manufacturing complexities and key processes in development of biosimilars
- Identify key steps in the regulatory approval process for biosimilars
- Assess barriers to application of biosimilars in clinical practice and the impact of real-world evidence to address these
- Apply safety and efficacy data regarding biosimilars to the care of patients with hematologic malignancies
Faculty, Staff and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.Chair
Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas, USA
Disclosures: Grant/Research Support: AbbVie, Astellas, Bristol Myers Squibb, Daiichi-Sankyo, Forty Seven, Genentech, Gilead Sciences, ImmunoGen, Incyte, Kite Pharma, Novartis, Novimmune SA, Pfizer, Roche, Trillium Therapeutics; Consultant: AbbVie, Actinium Pharmaceuticals, Amgen, Astellas, Bristol Myers Squibb, Daiichi-Sankyo, Forty Seven, Genentech, Gilead Sciences, ImmunoGen, Incyte, Jazz, Novartis, Otsuka, Pfizer, Roche, Trillium Therapeutics.
Faculty
Director
Medical Research Hematology Unit
Romagnolo Scientific Institute for the Study and Treatment of Cancer
Meldola, Italy
Disclosures: Claudio Cerchione, MD, PhD, has no relevant financial relationships with ineligible companies.
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas, USA
Disclosures: Grant/Research Support: AbbVie Inc., Adaptive Biotechnologies; Amgen Inc., Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, Pfizer Inc., Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company.
Professor of Medicine
Chair, Department of Leukemia
Samsung Distinguished University Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas, USA
Disclosures: Grant/Research Support: AbbVie, Amgen, Ascentage Pharma, Bristol Myers Squibb, Daiichi-Sankyo, ImmunoGen, Jazz Pharmaceuticals, Pfizer, Sanofi.
Associate Professor
Department of Experimental, Diagnostic and Specialty Medicine
University of Bologna
Bologna, Italy
Scientific Director
Romagnolo Scientific Institute for the Study and Treatment of Cancer
Meldola, Italy
Disclosures: Grant/Research Support: Daiichi Sankyo, Incyte, Pfizer; Consultant: AbbVie, Pfizer, Roche; Speakers’ Bureau: Novartis.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
